| Revision as of 01:44, 19 July 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report [[Wikip← Previous edit |
Revision as of 19:08, 29 July 2011 edit undo155.91.28.231 (talk) corrected nomenclatureNext edit → |
| Line 30: |
Line 30: |
|
}} |
|
}} |
|
|
|
|
|
'''Vorapaxar''' (formerly SCH-530,348) is a ] receptor (]) antagonist based on the natural product ]. Discovered by ] and currently being developed by ], it is a experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.<ref name=chack>{{cite journal|author= Samuel Chackalamannil|title=Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity|journal=]|year=2008|doi =10.1021/jm800180e|volume= 51|pages= 3061–4|pmid=18447380|issue=11}}</ref> |
|
'''Vorapaxar''' (formerly SCH 530348) is a ] receptor (]) antagonist based on the natural product ]. Discovered by ] and currently being developed by ], it is a experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.<ref name=chack>{{cite journal|author= Samuel Chackalamannil|title=Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity|journal=]|year=2008|doi =10.1021/jm800180e|volume= 51|pages= 3061–4|pmid=18447380|issue=11}}</ref> |
|
|
|
|
|
In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions.<ref>, '']'', January 13, 2011</ref> Merck is uncertain whether further development of vorapaxar will continue. |
|
In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions.<ref>, '']'', January 13, 2011</ref> Merck is uncertain whether further development of vorapaxar will continue. |
In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions. Merck is uncertain whether further development of vorapaxar will continue.
